Seminars in Hematology
Volume 45, Issue 1 , Pages 8-13 , January 2008

Epidemiology of Myelodysplastic Syndromes

  • Sara S. Strom

      Affiliations

    • Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX.
    • Corresponding Author InformationAddress correspondence to Sara S. Strom, PhD, Department of Epidemiology, Unit 1340, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1340, Houston, TX 77230.
    • ,
  • Vivianne Vélez-Bravo

      Affiliations

    • Department of Epidemiology, University of Texas M.D. Anderson Cancer Center, Houston, TX.
    • ,
  • Elihu H. Estey

      Affiliations

    • Leukemia Department, University of Texas M.D. Anderson Cancer Center, Houston, TX.

References 

  1. Aul C, Gattermann N, Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes. Leuk Lymphoma. 1995;16:247–262
  2. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: Incidence and survival in the United States. Cancer. 2007;109:1536–1542
  3. Aul C, Gatterman N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol. 1992;82:358–367
  4. Park D, Koeffler H. Therapy-related myelodysplastic syndromes. Semin Hematol. 1996;33:256–273
  5. Levine E, Bloomfield C. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992;19:47–84
  6. Cartwright RA. Incidence and epidemiology of myelodysplastic syndromes. In:  Mufti GJ,  Galton DA editor. The Myelodysplastic Syndromes. New York, NY: Churchill Livingstone; 1992;p. 23–32
  7. Shimizu H, Matsushita Y, Aoki K, Nomura T, Yoshida Y, Mizoguchi H. Prevalence of the myelodysplastic syndromes in Japan. Int J Hematol. 1995;61:17–22
  8. Germing U, Strupp C, Kundgen A, Bowen D, Aul C, Haas R, et al. No increase in age-specific incidence of myelodysplastic syndromes. Haematologica. 2004;89:905–910
  9. Reizenstein P, Dabrowsky L. Increasing prevalence of the myelodysplastic syndrome: An international Delphi study. Anticancer Res. 1991;11:1069–1070
  10. Aul C, Bowen D, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998;83:71–86
  11. Giralt M, Franco-García E, Girlado P, Gutiérrez M, Angos JA, Perella M, et al. Incidence rates of MDS in a Northern-Spanish area. Leuk Res. 1999;23(suppl 1):S158
  12. Maynadie M, Verret C, Moskovtchenko P, Mugneret F, Petrella T, Caillot D, et al. Epidemiological characteristics of myelodysplastic syndrome in a well-defined French population. Br J Cancer. 1996;74:288–290
  13. Radlund A, Thiede T, Hansen S, Carlson M, Engquist L. Incidence of myelodysplastic syndromes in a Swedish population. Eur J Haematol. 1995;54:153–156
  14. Phillips MJ, Cull GM, Ewings M. Establishing the difference of myelodysplasia syndrome. Br J Haematol. 1994;88:896–897
  15. Minamoto T, Mai M, Ronai Z. Environmental factors as regulators and effectors of multistep carcinogenesis. Carcinogenesis. 1999;20:519–527
  16. Chen H, Sandler D, Taylor J, Shore D, Liu D, Bloomfield C, et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet. 1996;347:295–297
  17. Sasai Y, Horiike S, Misawa S, Kaneko H, Kobayashi M, Fujii H, et al. Genotype of glutathione S-transferase and other genetic configurations in myelodysplasia. Leuk Res. 1999;23:975–981
  18. Yang L, Zou X, Zhang MR, Zhang Y, Hao YS, Xiao ZJ. Investigation of GSTT1, GSTM1 and NQO1 genes polymorphisms in myelodysplastic syndromes. Zhonghua Xue Ye Xue Za Zhi. 2005;26:674–677
  19. Preudhomme C, Nisse C, Hebbar M, Vanrumbeke M, Brizard A, Lai J, et al. Glutathione S-transferase theta 1 gene defect in myelodysplastic syndromes and their correlation with karyotype and exposure to potential carcinogens. Leukemia. 1997;11:1580–1582
  20. Basu T, Gale R, Langabeer S, Linch D. Glutathione S-transferase theta 1 (GSTT1) gene defect in myelodysplasia and acute myeloid leukaemia. Lancet. 1997;349:1450
  21. Atoyebi W, Kusec R, Fidler C, Peto T, Boultwood J, Wainscoat J. Glutathione S-transferase gene deletions in myelodysplasia. Lancet. 1997;349:1450–1451
  22. Bolufer P, Collado M, Barragan E, Calasanz MJ, Colomer D, Tormo M, et al. Profile of polymorphisms of drug-metabolizing enzymes and the risk of therapy-related leukaemia. Br J Haematol. 2007;136:590–596
  23. Guillem VM, Collado M, Terol MJ, Calasanz MJ, Esteve J, Gonzalez M, et al. Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies. Leukemia. 2007;21:1413–1422
  24. Liu TC, Lin SF, Chen TP, Chang JG. Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep. 2002;9:327–329
  25. Mayer R, Cannellos G. Primary myelodysplastic syndrome and secondary preleukemic disorders. In:  Henderson E,  Lister T,  Greaves M editor. Leukemia. ed 6. Philadelphia, PA: Saunders; 1996;p. 513–534
  26. Van Leeuwen FE. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. Baillieres Clinical Haematol. 1996;9:57–85
  27. Smith MA, Rubinstein L, Anderson JR, Arthur D, Catalano PJ, Freidlin B, et al. Secondary leukemia and or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17:569–577
  28. Andersen MK, Johansson B, Larsen SO, Pedersen-Bjergaard J. Chromosomal abnormalities in secondary MDS and AML: Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Haematologica. 1998;83:483–488
  29. Boice JD, Land CE, Preston DL. Ionizing radiation. In:  Schottenfeld D,  Fraumeni JF editor. Cancer Epidemiology and Prevention. Oxford, UK: Oxford University Press; 1996;p. 319–354
  30. Le Noire C. Sur un cas de prupura attribuè á l’intoxication par le benzene. Bull Mem Soc Med Hop Paris. 1897;14:1251–1253
  31. Aksoy M, Dincol K, Erdem S, Dincol G. Acute leukemia due to chronic benzene exposure. Am J Med. 1972;52:160–166
  32. Hayes R, Yin S, Dosemeci M, Li G, Wacholder S, Chow W, et al. Mortality among benzene-exposed workers in China. Environ Health Perspect. 1996;104(suppl 6):1349–1352
  33. Yin S, Hayes R, Linet M, Li G, Dosemeci M, Travis L, et al. A cohort study of cancer among benzene-exposed workers in China: Overall results. Am J Ind Med. 1996;29:227–235
  34. Nilsson R, Nordlinder R, Horte L, Jarvholm B. Leukaemia, lymphoma and multiple myeloma in seamen on tankers. Occup Environ Med. 1998;55:517–521
  35. Christie D, Robinson K, Gordon I, Bisby J. A prospective study in the Australian petroleum industry (II. Incidence of cancer). Br J Ind Med. 1991;48:511–514
  36. Tunca B, Egeli U. Cytogenetic findings on shoe workers exposed long-term to benzene. Environ Health Perspect. 1996;104(suppl 6):1313–1317
  37. Dosemeci M, Yin SN, Linet M, Wacholder S, Rothman N, Li GL, et al. Indirect validation of benzene exposure assessment by association with benzene poisoning. Environ Health Perspect. 1996;104(suppl 6):1343–1347
  38. West R, Stafford D, Farrow A, Jacobs A. Occupational and environmental exposures and myelodysplasia: A case-control study. Leuk Res. 1995;19:127–139
  39. Ciccone G, Mirabelli D, Levis A, Gavarotti P, Rege-Cambrin G, Davico L, et al. Myeloid leukemias and myelodysplastic syndromes: chemical exposure, histologic subtype and cytogenetics in a case-control study. Cancer Genet Cytogenet. 1993;68:135–139
  40. Rigolin GM, Cuneo A, Roberti MG, Bardi A, Bigoni R, Piva N, et al. Exposure to myelotoxic agents and myelodysplasia: Case-control study and correlation with clinicobiological findings. Br J Haematol. 1998;103:189–197
  41. Nisse C, Lorthois C, Dorp V, Eloy E, Haguenoer J, Fenaux P. Exposure to occupational and environmental factors in myelodysplastic syndromes: Preliminary results of a case-control study. Leukemia. 1995;9:693–699
  42. Goldberg H, Lusk E, Moore J, Nowell PC, Besa PC. Survey of exposure to genotoxic agents in primary myelodysplastic syndrome—Correlation with chromosome patterns and data in patients without haematological disease. Cancer Res. 1990;50:6876–6881
  43. Strom SS, Gu Y, Gruschkus SK, Pierce SA, Estey EH. Risk factors of myelodysplastic syndromes: A case-control study. Leukemia. 2005;19:1912–1918
  44. Albin M, Bjork J, Welinder H, Tinnerberg H, Mauritzson N, Billstrom R, et al. Cytogenetic and morphologic subgroups of myelodysplastic syndromes in relation to occupational and hobby exposures. Scand J Work Environ Health. 2003;29:378–387
  45. Brownson R, Novotny T, Perry M. Cigarette smoking and adult leukemia: A meta-analysis. Arch Intern Med. 1993;153:469–475
  46. Pasqualetti P, Festuccia V, Acitelli P, Collacciana A, Giusti A, Casale R. Tobacco smoking and risk of haematological malignancies in adults: A case-control study. Br J Haematol. 1997;97:659–662
  47. Ido M, Nagata C, Kawakami N, Shimizu H, Yoshida Y, Nomura T, et al. A case-control study of myelodysplastic syndromes among Japanese men and women. Leuk Res. 1996;20:727–731
  48. Bjork J, Albin M, Mauritzson N, Stromberg U, Johansson B, Hagmar L. Smoking and myelodysplastic syndromes. Epidemiology. 2000;11:285–291
  49. Nisse C, Haguenoer JM, Granbastuen B, Preudhomme C, Fontaine B, Brillet JM, et al. Occupational and environmental risk factors of the myelodysplastic syndromes in the North of France. Br J Haematol. 2001;12:927–935
  50. Moloney W. Radiogenic leukemia revisited. Blood. 1987;70:905–908
  51. Shimizu Y, Schull WJ, Kato H. Cancer risk among atomic bomb survivors (The RARF Life Span Study. Radiation Effects Research Foundation). JAMA. 1990;264:601–604
  52. Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, et al. Cancer incidence in atomic bomb survivors (Part III: Leukemia, lymphoma and multiple myeloma, 1950-1987). Radiat Res. 1994;137(suppl 2):S68–S97
  53. Shimizu H, Pierce DA, Preston DL, Mabuchi K. Studies of the mortality of atomic bomb survivors (Report 12, part II. Noncancer mortality: 1950-1990). Radiat Res. 1999;152:374–389
  54. Matsuo T, Tomonaga M, Bennet J, Kuriyama K, Imanaka F, Kuramoto A, et al. Reclassification of leukemia among A-bomb survivors in Nagasaki using French-American-British (FAB) classification for acute leukemia. Jpn J Clin Oncol. 1988;18:91–96
  55. Correa A, Mohan A, Jackson L, Perry H, Helzlsouer K. Use of hair dyes, hematopoietic neoplasms, and lymphomas: A literature review (review) (I. Leukemias and myelodysplastic syndromes). Cancer Invest. 2000;18:366–380
  56. Nagata C, Shimizu H, Hirashima K, Kakishita E, Fujimura K, Niho Y, et al. Hair dye use and occupational exposure to organic solvents as risk factors for myelodysplastic syndrome. Leuk Res. 1999;23:57–62
  57. Williams RR, Horm JW. Association of cancer sites with tobacco and alcohol consumption and socioeconomic status of patients: Interview study from the Third National Cancer Survey. J Natl Cancer Inst. 1997;58:525–547
  58. Blackwelder WC, Yano K, Rhoads GG, Kagan A, Gordon T, Palesch Y. Alcohol and mortality: The Honolulu Heart Study. Am J Med. 1980;68:164–169
  59. Hinds MW, Kolonel LN, Lee T, Hirohata T. Association between cancer incidence and alcohol and cigarette consumption among five ethnic groups in Hawaii. Br J Cancer. 1980;41:929–940
  60. Carstensen JM, Bygren LO, Hatschek T. Cancer incidence among Swedish brewery workers. Int J Cancer. 1990;45:393–396
  61. Brown LM, Gibson R, Burmeister LF, Schuman LM, Everett GD, Blair A. Alcohol consumption and risk of leukemia, non-Hodgkin’s lymphoma, and multiple myeloma. Leuk Res. 1992;16:979–984
  62. Pasqualetti P, Casale R, Colantonio D, Collacciani A. Occupational risk for hematological malignancies. Am J Hematol. 1991;38:147–149
  63. Dalamage M, Petridou E, Cook F, Trichopoulos D. Risk factors for myelodysplastic syndromes: A case-control study in Greece. Cancer Causes Control. 2002;13:603–608
  64. Bianchini F, Vainio H. Wine and resveratrol: Mechanisms of cancer prevention?. Eur J Cancer Prev. 2003;12:417–425
  65. Tsan MF, White JE, Maheshwari JG, Chikkappa G. Anti-leukemia effect of resveratrol. Leuk Lymphoma. 2002;43:983–987
  66. Surh YJ, Hurh YJ, Kang E, Kong G, Lee SJ. Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett. 1999;140:1–10
  67. Raza A. Hypothesis: myelodysplastic syndromes may have a viral etiology. Int J Hematol. 1998;68:245–256
  68. Palmer C, Heerema N, Greist A, Tricot G, Hoffman R. Cytogenetic findings in siblings with a myelodyspastic syndrome. Cancer Genet Cytogenet. 1987;2:241–249
  69. Grimwade D, Stephenson J, De Silva C, Dalton R, Mufti G. Familial MDS with 5q- abnormality. Br J Haematol. 1993;84:536–538
  70. Marsden K, Challis D, Kimber R. Familial myelodysplastic syndrome with onset late in life. Am J Hematol. 1995;49:153–156
  71. Olopade O, Roulston D, Baker T, Narvid S, Le Beau MM, Freireich EJ, et al. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia. 1996;10:669–674
  72. Mandla S, Goobie S, Kumar R, Hayne O, Zayed E, Guernsey D, et al. Genetic analysis of familial myelodysplastic syndrome: Absence of linkage to chromosomes 5q31 and 7q22. Cancer Genet Cytogenet. 1998;105:113–118
  73. Hasle H, Niemeyer C. Myelodysplastic syndromes in myelomonocytic leukemia in children. In:  Bennet J editors. The Myelodysplastic Syndromes: Pathobiology and Clinical Management. New York, NY: Dekker; 2002;p. 299–344
  74. Hasle H, Olsen JH. Cancer in relatives of children with myelodysplastic syndrome, acute and chronic myeloid leukaemia. Br J Haematol. 1997;97:127–131

 Supported by Grants No. CA100632 and CA115180 form the National Cancer Institute.

PII: S0037-1963(07)00154-0

doi: 10.1053/j.seminhematol.2007.10.003

Seminars in Hematology
Volume 45, Issue 1 , Pages 8-13 , January 2008

Article Tools